COVID tests subject to continued ‘price-gouging’ To view this email as a web page,
click here With pandemic restrictions lifted, FDA restarts U.S. inspections and seeks to whittle its massive backlog UPDATED Coronavirus tracker: AHIP study finds continued 'price-gouging' for COVID tests COVID-19 tracker: Sanofi, GSK vaccine under review in Europe; Delta variant makes up 83% of new US cases Another medical provider group pushing healthcare employers to require COVID-19 vaccination BioNTech makes a splash in cell therapy with purchase of factory, R&D platform from Gilead's Kite Featured Story | By Kevin Dunleavy Hamstrung by the coronavirus pandemic, the FDA accumulated a huge backlog of more than 20,000 inspections. The agency now is free to starting reducing that list, at least in the United States, where it has resumed normal operations. read more |
| |
|---|
|
Top Stories By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner Sanofi and GlaxoSmithKline's protein-based vaccine is now under a rolling review in Europe. The highly infectious Delta variant now makes up 83% of new U.S. infections, the head of the CDC said. And more. read more By Dave Muoio The industry organization joins numerous professional groups backing mandatory COVID-19 vaccination policies as nationwide hospitalization rates tick upward. No small number of hospitals and health systems have already chosen to implement the requirements for a collective hundreds of thousands of healthcare staff. read more By Fraiser Kansteiner Germany’s BioNTech has already risen to international prominence thanks to its Pfizer-partnered COVID-19 vaccine. Now, the mRNA specialist has lined up a deal for its first U.S. factory as it looks to make a big splash in cell therapy. read more |
|
